NCT02837705CompletedNot Applicable
Therapeutic Antibodies Against Prion Diseases From PRNP Mutation Carriers
University of Zurich7 sites in 7 countries213 target enrollmentStarted: September 1, 2015Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- University of Zurich
- Enrollment
- 213
- Locations
- 7
- Primary Endpoint
- Anti-Prion protein autoantibody levels
Study Overview
Brief Summary
The human Prion diseases can be classified into sporadic, acquired and inherited forms. Inherited forms usually manifest in higher age so there have to be factors preventing Prion propagation in young mutation carriers. Antibodies against the flexible tail of Prions have been shown to be protective in mice. The investigators intend to screen mutation carriers and controls for the presence of Prion autoantibodies.
Study Design
- Study Type
- Observational
- Observational Model
- Case Control
- Time Perspective
- Cross Sectional
Eligibility Criteria
- Ages
- 1 Year to 99 Years (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Relatives of patients of genetic Prion diseases
- •Obtained informed consent
Exclusion Criteria
- •No informed consent
Outcomes
Primary Outcomes
Anti-Prion protein autoantibody levels
Time Frame: Baseline, up to 90 years
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (7)
Loading locations...
Similar Trials
Recruiting
Not Applicable
A Natural History Study of Preclinical Genetic Creutzfeldt-Jakob Disease (CJD)Creutzfeldt-Jakob Disease (CJD)NCT05746715Tel-Aviv Sourasky Medical Center126
Unknown
Not Applicable
Immunological Characteristics of Patients With PID and IBDInflammatory Bowel DiseasesPrimary Immune Deficiency DisorderNCT03148028Sheba Medical Center45
Unknown
Not Applicable
Interest Balance Auto-immune Population in Patients With Focal Epilepsy of Unknown Cause, Not Structural, Not Genetics, Newly DiagnosedEpilepsyNCT02885207University Hospital, Strasbourg, France200
Completed
Phase 1
Multivirus-specific Cytotoxic T Lymphocytes (mCTL)Refractory Viral InfectionsNCT02510404Catherine Bollard1
Unknown
Not Applicable
New Biomarkers for Diagnosis and Follow-up of Patients With LRBA or CTLA4 DeficienciesLRBA DeficiencyCTLA4 HaploinsufficiencyNCT04377867Marmara University30